| abstract |
In some aspects, the invention relates to antibody-drug conjugates comprising an anti-CD19 antibody, a linker and an active agent. The antibody-drug conjugate may comprise a spontaneously degradable group. The linker may comprise an O-substituted oxime, for example, wherein the argon atom of the oxime is substituted by a group covalently linking the oxime to the active agent; and the ruthenium carbon atom is covalently attached to the oxime The group of the antibody is substituted. |